

## DAFTAR PUSTAKA

1. Departemen Kesehatan RI. Pedoman nasional penanggulangan tuberkulosis. Edisi ke-2. Cetakan ke-1. Jakarta: Depkes RI; 2007.
2. Minister of health's point in celebrating world tuberculosis day 2007 [serial online] 2007 Mar 23 [cited 2008 Jun 18]. Available from: <http://www.depkes.go.id/en/2303mi.htm>.
3. WHO. Tuberculosis [serial online]. Available from: <http://www.who.int/mediacentre/factsheets/fs104/en/index.html>
4. Zulkifli A, Asril B. Tuberkulosis paru. Dalam: Aru WS, Setiohadi B. Buku ajar ilmu penyakit dalam. Edisi ke-4. Jakarta: Balai Penerbit IPD Fakultas Kedokteran Universitas Indonesia; 2006. h. 990-1004.
5. Aditama Tjandra Y. Klasifikasi tuberkulosis dalam tuberkulosis pedoman diagnosis dan penatalaksanaan di Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia; 2006.
6. Parwati I, Alisjahbana B, Rosana Y, Sudiro TM. Multi drug resistant TB in new and previous treated pulmonary tuberculosis patient in west java. 3<sup>rd</sup> Symposium of Indonesia Antimicrobacteria Resistance Watch; 2006.
7. Mario CR, Richard JO. Tuberculosis. In : Kasper DL, Braunwald E, Fauci A, Hauser S, Longo D, Jameson JL, editors. Harrison's: Principles of internal medicine. 16<sup>th</sup> ed. New York: McGraw-Hill Profesional; 2004. p.1006.
8. Alexander JM, Arlene HS. Infectious disease. In: Vinar K, Abul KA, Nelson F. Robbins and cotran: Pathologic basis of disease. 7<sup>th</sup> ed. Philadelphia: Elsevier Saunders; 2005. p. 381-6.
9. Pieters J, Gatfield J. Hijacking the host: Survival of pathogenic mycobacteria inside macrophages. Trends Microbiol 2002; 10: 142.
10. Glickman MS, Jacob WR. Microbial pathogenesis of mycobacterium tuberculosis: Dawn of a discipline. Cell 2003; 104: 477.
11. Fratti RA, Backer JM, Gruenberg J. Role of phosphatidylinositol 3-kinase and rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. J Cell Biol 2001; 154: 631.

12. Bellamy R, Ruwende C. Variations in the NRAMP1 gene and susceptibility to tuberculosis. *New England Journal Med* 1998; 338: 640.
13. Youl D, Hussel T, Dougan G. Chronic bacterial infection: Living with unwanted guest. *Nat Immunol* 2002; 3: 1026.
14. Yamamura M, Uyemura K, Deans RJ. Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. *Science* 1991; 254: 277.
15. Geo FB, Janet SB, Stephen AM. Jawetz, melnick, & adelberg's medical microbiology. 24<sup>th</sup> ed. USA: McGraw-Hill Companies; 2007.
16. Poojary A, Nataraj G, Kanade S, Mehta P, Baveja S. Rapid antibiotic susceptibility testing of *Mycobacterium tuberculosis*: Its utility in resource poor settings. *Indian J Med Microbiol* [serial online] 2006 [cited 2008 Apr 22];24:268-72. Available from: <http://www.ijmm.org/text.asp?2006/24/4/268/29385>.
17. Palomino JC, Martin A, Camacho M, Guerra H, Swings J, Portaels F. Resazurin microtiter assay plate: Simple and inexpensive method for detection of rifampicin resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 2002; 46: 2720-2.
18. Caviedes L, Lee TS, Gilman RH, Sheen P, Spellman E, Lee EH, et al. Rapid, efficient detection and rifampicin susceptibility testing of *M. tuberculosis* in sputum by microscopic observation of broth cultures. *J Clin Microbiol* 2000; 38: 1203-8.
19. Petri WA. Drug used in the chemotherapy of tuberculosis, *Mycobacterium avium* complex disease, and leprosy. In: Hardman JG, Limbird LE, Gilman AG, editors. *Goodman & Gilman's the pharmacological basis of therapeutics*. 10th ed. USA: McGraw-Hill Companies; 2001. p.1280-1.
20. WHO. Surveillance of drug-resistant tuberculosis in south-east asia. Workshop [serial online] 2006 Apr 27 [cited 2008 Mei 23]. Available from: [http://www.searo.who.int/EN/Section10/Section17/Section58/Section1670\\_7125.htm](http://www.searo.who.int/EN/Section10/Section17/Section58/Section1670_7125.htm).
21. Rattan A, Kalia A, Ahmad N. Multidrug-resistant *Mycobacterium tuberculosis*: Molecular perspectives. All India Institute of Medical Science

- [serial online] [cited 2008 Juli 15]. Available from: <http://www.cdc.gov/ncidod/EID/vol4no2/rattan.htm#ref01>
22. Cooksey RC, Morlock GP, Mcqueen A, Glickman SE, Crawford JT. Characterization of rifampisin resistance mechanisms among *Mycobacterium tuberculosis* isolates from patients in new york city. American Society for Microbiology [serial online] 1996 Feb 12 [cited 2008 Mei 23];40:1186-8. Available from: <http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=163288&blobtype=pdf>
  23. WHO/ IUATLD. Global working group on anti-tuberculosis drug surveillance. Guidelines for surveillance of drug resistance in tuberculosis. Geneva: WHO. 1997; 96: 216.
  24. Dam T, Isa M, Bose M. Drug-sensitivity profile of clinical *Mycobacterium tuberculosis* isolates – a retrospective study from a chest-disease institute in india. Journal of Medical Microbiology [serial online] 2005 [cited 2008 Apr 22];54:269–71. Available from: <http://jmm.sgmjournals.org/cgi/content/abstract/54/3/269>.
  25. World Health Organization. Global tuberculosis control. WHO report 2001. World Health Organization: Geneva; Switzerland. WHO/CDS/TB/2001.287.
  26. Borgdorff MW, Nagelkerke NJ, Dye C, Nunn P. Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis 2000;4(2):123-32.
  27. Pablos-Mendez A, Ravaglione MC, Laszlo A. Global surveillance for anti-tuberculosis drug resistance; 1994-1997. New Engl J Med. 1998;338:1641-9.
  28. Jesudason MV, Mukundan U, Saaya R, Vanitha K, Lalitha MK. Resistance of *Mycobacterium tuberculosis* to the first line anti tubercular drugs - A twenty year review. Indian J Med Microbiol [serial online] 2003 [cited 2008 Jul 23];21:127-8. Available from: <http://www.ijmm.org/article.asp?issn=0255-0857;year=2003;volume=21;issue=2;spage=127;epage=128;aulast=Jesudason>.